WEIGHT LOSS DRUGS LINKED TO HAIR LOSS IN STUDY OF 50,000 PEOPLE

A study analysing data from approximately 50,000 people found that GLP-1 agonist drugs, including Mounjaro, Ozempic and Wegovy, were associated with a 37 to 68 per cent higher risk of alopecia compared to other diabetes medications. The research was published in the British Medical Journal. Regulatory bodies including the UK's MHRA and the US FDA have received hundreds of reports of hair loss connected to these drugs. The FDA is currently evaluating the matter as a potential safety signal.

The hair loss identified in the study is typically non-scarring alopecia, meaning hair follicles remain intact and regrowth may be possible. Researchers propose that rapid weight loss, reduced caloric intake and associated physiological stress or micronutrient deficiencies are the most likely mechanisms responsible for the hair loss. GLP-1 agonists are medications originally developed to treat type 2 diabetes but are increasingly prescribed for weight loss.

The findings add to emerging reports of side effects associated with these widely used drugs. Doctors and patients have increasingly reported concerns about various effects linked to GLP-1 use as prescription numbers have risen substantially. The study's findings may prompt further scrutiny of these medications by regulatory authorities as they continue to evaluate safety data.